{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T06:35:27Z","timestamp":1792564527701,"version":"4.5.0"},"reference-count":40,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031315","name":"AstraZeneca UK","doi-asserted-by":"publisher","award":["ESR-22-21856"],"award-info":[{"award-number":["ESR-22-21856"]}],"id":[{"id":"10.13039\/100031315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2025,12,2]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>In patients with chronic obstructive pulmonary disease (COPD), severe exacerbations (ECOPDs) impose significant morbidity and mortality. Current guidelines emphasise using ECOPD history to inform preventive treatments but offer limited guidance for risk stratification for the first severe ECOPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed and validated PRECISE-X using a cohort of newly diagnosed COPD patients from the UK\u2019s Clinical Practice Research Datalink (2004\u20132022), to predict first severe ECOPD over 5 years (primary outcome) and 12 months (secondary outcome). Predictors were selected via clinical expertise and data-driven methods. Internal-external cross-validation was performed across practice regions to evaluate the model\u2019s out-of-sample performance in terms of discrimination (c-statistic), calibration and net benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 2\u200919\u2009015 patients (mean age 66.0; 42.4% female). Observed risk of first severe ECOPD was 29.5% at 5 years (4.2% at 1 year). The final model included four mandatory predictors (sex, age, Medical Research Council dyspnoea score and forced expiratory volume in 1 second) and 28 optional predictors. In internal-external cross-validation, the average out-of-sample c-statistic was 0.836 (95% CI 0.827 to 0.846) for 5-year prediction and 0.756 (95% CI 0.746 to 0.766) for 1-year prediction. Calibration across regions was robust, and the model showed positive NB across a wide range of risk thresholds. In a secondary validation assessment among those with available spirometry data with confirmed airflow obstruction, the model was well calibrated and had only a modest decline in discriminatory performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PRECISE-X accurately predicts the first severe COPD exacerbation using routine clinical data, supporting earlier risk stratification and proactive disease management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2025-223770","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T18:25:24Z","timestamp":1767205524000},"page":"541-547","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Development and validation of PRECISE-X model: predicting first severe exacerbation in COPD"],"prefix":"10.1136","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0419-7862","authenticated-orcid":false,"given":"Mohsen","family":"Sadatsafavi","sequence":"first","affiliation":[{"name":"Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9850-9520","authenticated-orcid":false,"given":"Marc","family":"Miravitlles","sequence":"additional","affiliation":[{"name":"Respiratory Department, Vall d\u2019Hebron University Hospital \/ Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus. CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0149-4869","authenticated-orcid":false,"given":"Jennifer K","family":"Quint","sequence":"additional","affiliation":[{"name":"School of Public Health, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9516-4862","authenticated-orcid":false,"given":"Valeria","family":"Perugini","sequence":"additional","affiliation":[{"name":"Respiratory Effectiveness Group, Cambridgeshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Tavakoli","sequence":"additional","affiliation":[{"name":"Meta Health Informatics, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Emil","family":"Amegadzie","sequence":"additional","affiliation":[{"name":"Epidemiology and Intelligence Services and Faculty of Pharmaceutical Sciences, British Columbia Centre for Disease Control and The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2356-9366","authenticated-orcid":false,"given":"Bernardino","family":"Alcazar Navarrete","sequence":"additional","affiliation":[{"name":"Respiratory Department, Hospital Universitario Virgen de las Nieves, ibs.Granada, Universidad de Granada, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"2026051403202038000_81.6.541.1","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00838-2023","article-title":"Global mortality and readmission rates following COPD exacerbation-related hospitalisation: a meta-analysis of 65\u2009945 individual patients","volume":"10","author":"Waeijen-Smit","year":"2024","journal-title":"ERJ Open Res"},{"key":"2026051403202038000_81.6.541.2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2005.040527"},{"key":"2026051403202038000_81.6.541.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g5237","article-title":"Management and prevention of exacerbations of COPD","volume":"349","author":"Aaron","year":"2014","journal-title":"BMJ"},{"key":"2026051403202038000_81.6.541.4","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-201518"},{"key":"2026051403202038000_81.6.541.5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2023-002153","article-title":"Elucidating the risk of cardiopulmonary consequences of an exacerbation of COPD: results of the EXACOS-CV study in Germany","volume":"11","author":"Vogelmeier","year":"2024","journal-title":"BMJ Open Resp Res"},{"key":"2026051403202038000_81.6.541.6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S2213-2600(24)00038-9","article-title":"MACE in COPD: addressing cardiopulmonary risk","volume":"12","author":"Hurst","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026051403202038000_81.6.541.7","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.2147\/COPD.S139470","article-title":"Impact and prevention of severe exacerbations of COPD: a review of the evidence","volume":"12","author":"Halpin","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026051403202038000_81.6.541.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.09.009"},{"key":"2026051403202038000_81.6.541.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbres.2023.02.009"},{"key":"2026051403202038000_81.6.541.10","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l5358","article-title":"Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease: systematic review and critical appraisal","volume":"367","author":"Bellou","year":"2019","journal-title":"BMJ"},{"key":"2026051403202038000_81.6.541.11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab312"},{"key":"2026051403202038000_81.6.541.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.2.180"},{"key":"2026051403202038000_81.6.541.13","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","year":"2024","journal-title":"BMJ"},{"key":"2026051403202038000_81.6.541.14","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"2026051403202038000_81.6.541.15","unstructured":"Clinical Practice Research Datalink . CPRD aurum May 2022 (version 2022.05.001) [data set]. Clinical practice research datalink. 2022. Available: https:\/\/www.cprd.com\/cprd-aurum-may-2022-dataset [accessed 06 Jan 2025]"},{"key":"2026051403202038000_81.6.541.16","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/pds.5188","article-title":"Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real-world trials","volume":"30","author":"Requena","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026051403202038000_81.6.541.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005540","article-title":"Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD)","volume":"4","author":"Quint","year":"2014","journal-title":"BMJ Open"},{"key":"2026051403202038000_81.6.541.18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0292876","article-title":"Exploring the impact of varying definitions of exacerbations of chronic obstructive pulmonary disease in routinely collected electronic medical records","volume":"18","author":"Whittaker","year":"2023","journal-title":"PLoS One"},{"key":"2026051403202038000_81.6.541.19","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201710-2029OC"},{"key":"2026051403202038000_81.6.541.20","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S117867"},{"key":"2026051403202038000_81.6.541.21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151357","article-title":"Validation of the Recording of Acute Exacerbations of COPD in UK Primary Care Electronic Healthcare Records","volume":"11","author":"Rothnie","year":"2016","journal-title":"PLoS One"},{"key":"2026051403202038000_81.6.541.22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-074819","article-title":"Evaluation of clinical prediction models (part 1): from development to external validation","volume":"384","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"2026051403202038000_81.6.541.23","doi-asserted-by":"publisher","DOI":"10.7326\/M22-0844"},{"key":"2026051403202038000_81.6.541.24","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1177\/09622802231165001","article-title":"Imputation and missing indicators for handling missing data in the development and deployment of clinical prediction models: A simulation study","volume":"32","author":"Sisk","year":"2023","journal-title":"Stat Methods Med Res"},{"key":"2026051403202038000_81.6.541.25","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7913"},{"key":"2026051403202038000_81.6.541.26","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1844"},{"key":"2026051403202038000_81.6.541.27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1183\/13993003.01186-2021","article-title":"Moving beyond AUC: decision curve analysis for quantifying net benefit of risk prediction models","volume":"58","author":"Sadatsafavi","year":"2021","journal-title":"Eur Respir J"},{"key":"2026051403202038000_81.6.541.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.005"},{"key":"2026051403202038000_81.6.541.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909883"},{"key":"2026051403202038000_81.6.541.30","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S49609"},{"key":"2026051403202038000_81.6.541.31","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S2213-2600(19)30397-2","article-title":"The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study","volume":"8","author":"Adibi","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026051403202038000_81.6.541.32","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101574","article-title":"ACCEPT 2\u00b70: Recalibrating and externally validating the Acute COPD exacerbation prediction tool (ACCEPT)","volume":"51","author":"Safari","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2026051403202038000_81.6.541.33","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.152876"},{"key":"2026051403202038000_81.6.541.34","doi-asserted-by":"crossref","first-page":"106091","DOI":"10.1016\/j.rmed.2020.106091","article-title":"Clinical and spirometric variables are better predictors of COPD exacerbations than routine blood biomarkers","volume":"171","author":"Nu\u00f1ez","year":"2020","journal-title":"Respir Med"},{"key":"2026051403202038000_81.6.541.35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.amjmed.2018.05.003","article-title":"Chronic Obstructive Pulmonary Disease Exacerbations: A Need for Action","volume":"131","author":"Anzueto","year":"2018","journal-title":"Am J Med"},{"key":"2026051403202038000_81.6.541.36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191243","article-title":"The association between previous and future severe exacerbations of chronic obstructive pulmonary disease: Updating the literature using robust statistical methodology","volume":"13","author":"Sadatsafavi","year":"2018","journal-title":"PLoS One"},{"key":"2026051403202038000_81.6.541.37","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-005-3215-y"},{"key":"2026051403202038000_81.6.541.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02905-y"},{"key":"2026051403202038000_81.6.541.39","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.arbres.2024.02.019","article-title":"Continuity of Care in Chronic Obstructive Pulmonary Disease Exacerbations: Challenges and Priorities","volume":"60","author":"Fern\u00e1ndez-Villar","year":"2024","journal-title":"Arch Bronconeumol"},{"key":"2026051403202038000_81.6.541.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.03.023"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2025-223770","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:21:33Z","timestamp":1778754093000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2025-223770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,5,14]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/thorax-2025-223770"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2025-223770","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]}}}